Comvita Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CVT.NZ research report →
Price Chart
About the company
Comvita Limited, along with its associated entities, specializes in the global production and distribution of natural health products. The company boasts a significant international presence, operating across diverse markets in Australasia, Asia (including China), North America, Europe, the Middle East, and Africa. Its extensive product portfolio features flagship items such as Manuka honey, propolis, and olive leaf extract.
- CEO
- Karl Gradon
- IPO
- 2003
- Employees
- 400
- HQ
- Te Puke, BP, NZ
Get TickerSpark's AI analysis on CVT.NZ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $58.13M
- P/E
- -0.61
- Fwd P/E
- 10.30
- PEG
- 0.03
- P/S
- 0.28
- P/B
- 0.97
- EV/EBITDA
- -40.79
- Div Yield
- 0.00%
- Gross Margin
- 42.29%
- Op Margin
- -12.79%
- Net Margin
- -44.47%
- ROE
- -165.47%
- ROIC
- -19.65%
Latest fiscal year · YoY change
- Revenue
- $192.43M-4.1%
- Gross Profit
- $82.70M-24.0%
- Op Income
- $-28,986,000
- Net Income
- $-104,759,000-35.4%
- EPS
- $-1.49-35.5%
- OCF Growth
- +540.1%
- FCF Growth
- +1510.5%
- 52W High
- $0.81
- 52W Low
- $0.43
- 50D MA
- $0.73
- 200D MA
- $0.68
- Beta
- 0.27
- RSI (14)
- 60
- Avg Volume
- 30.61K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Comvita said H1 FY26 marked a clear turnaround, with improved profitability, cash flow, and inventory reduction, while keeping full-year EBIT guidance unchanged and pushing ahead with recapitalization.· February 22, 2026
- H1 progress was broad-based: management said revenue growth, profitability, cash flow, net debt and inventory were all on or ahead of targets.
- Inventory fell to $68.3 million at 31 December 2025 from $145.8 million at December 2023, and net debt fell to $48.7 million.
- Full-year FY26 guidance was reaffirmed at normalized EBIT of $14.3 million, or $13.5 million pre-IFRS 16.
- North American club retail drove stronger sales and profit, while China remained challenging and ANZ was still weak.
- The board said recapitalization remains the top priority, with interest from existing/prospective investors and an offshore strategic investor at $0.80 per share, above a minimum $25 million raise.
Comvita did not give revenue, EPS, or gross margin for the period in the prepared remarks, but management said H1 FY26 delivered solid performance and improvements across key financial metrics. Mandy Tomkins-Dancey said inventory was reduced to $68.3 million at 31 December 2025 from $145.8 million at December 2023, cash conversion cycles improved from 484 days to 239 days, and net debt fell to $48.7 million from $62.4 million at the end of FY25 and $81.6 million a year earlier. She also said transaction costs of $1.4 million were included in H1 FY26 results. Full-year FY26 guidance was maintained at normalized EBIT of $14.3 million, or $13.5 million pre-IFRS 16. In Q&A, Mandy said gross margins are expected to return to around 51% in the medium term. Management said H2 still includes important seasonal and commercial drivers, with U.S. club retail currently in line with forecasts, the manuka season expected to be okay and yields likely in line with baseline assumptions, and Lunar New Year sales not yet known.
Karl Gradon framed the half as evidence that Comvita’s turnaround is taking hold, citing continued debt and inventory reduction, stronger execution, and benefits from new sales strategies in China, the U.S. and Southeast Asia. He repeatedly emphasized disciplined execution, stronger leadership capability, and a sharper focus on brand differentiation, innovation, and channel diversification. His tone was confident but pragmatic: the business is improving, but he stressed that the work is ongoing and the next six months require “ruthless execution.”
Mandy Tomkins-Dancey emphasized that H1 benefits came from strong U.S. club retail wholesale performance, disciplined cost management, and flow-through from FY25 cost-out actions such as procurement, formulation and freight efficiencies, leadership streamlining, and staff reductions. She highlighted that inventory normalization and sell-through of excess stock drove the cash conversion cycle improvement from 484 days to 239 days and helped reduce net debt to $48.7 million. She said the company expects gross margins to return to around 51% in the medium term, and that full-year normalized EBIT guidance remains $14.3 million, or $13.5 million pre-IFRS 16. She also noted that further working capital benefits in H2 are not expected to be as large as in H1.
Analysts focused on the dividend outlook, dilution from the recapitalization, U.S. sales durability, FX risk, inventory levels, and seasonality in gross margin and sales. Bridget Coates said a dividend remains a priority, but not something the board is considering in the near future because recapitalization and balance-sheet repair come first. On dilution, she said no exact outcome can be stated yet, though the board is mindful of protecting existing shareholders and the intended underwriting level is $0.80 per share. Karl Gradon said U.S. growth remains supported by low household penetration and a retail footprint that matches Comvita’s target demographic, while FX risks are being managed prudently under the hedge policy. He also said H1 club-channel strength was helped by winter seasonality and should soften in summer, while the full-year assumptions for U.S. growth and margins remain on track.
The call’s positive case is that Comvita appears to be executing a turnaround with measurable gains in profitability, cash conversion, inventory, and net debt. Management also sounded confident that North American club retail, product innovation, and diversification across channels and geographies can support further progress, while the full-year EBIT target was left unchanged.
The main risks are that China remains weak, ANZ is still challenging, and competition and commoditization are intensifying across markets. The recapitalization is still unresolved, dilution is not yet defined, and management said H2 will face important seasonal and commercial drivers, with further working-capital improvement unlikely to match H1.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 75.7%
- Shares Outstanding
- 72.22M
- Float Shares
- 54.70M
Our CVT.NZ coverage
Recent articles, reports, and earnings notes.
No research on CVT.NZ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CVT.NZ report →